A 12-year randomized clinical study of epithalamine (pineal gland peptide preparation) was carried out in elderly patients with coronary disease and accelerated aging of the cardiovascular system. Long-term treatment with epithalamine decreased the functional age and degree of cardiovascular aging; exercise tolerance increased. After 12 years the number of elderly subjects dead in the group treated by epithalamine was 28% lower than in the control group, despite the same basic therapy. Cardiovascular mortality was 2-fold lower in patients treated by epithalamine; the incidence of cardiovascular failure and respiratory diseases was 2-fold lower in this group. Long-term treatment with epithalamine was associated with a geroprotective effect on the long-term life prognosis in elderly subjects with accelerated aging.

No abstract

The paper shows that in elderly patients with uncompensated diabetes 2 types of course application of the drug Pankragen (RF Patent № 2242241) on Against the background of constant doses of glibenclamide leads to a significant decrease in plasma glucose levels on an empty stomach and 2 hours after the oral glucose tolerance test. An additional sugar -free effect is preserved two weeks after the cancellation of the pankration in 60 % of patients who continued to takeglibenclamide in previous doses. Pankochen has an additional sugar -free effect in patients with high initial resistance to insulinAnd hyperinSulinemia. Under the influence of the peptide preparation, the index decreases Homa insulin resistance. Any side effects or undesirable changes in laboratory indicators associated with the receptionObserving. Pankochen is shown to an elderly patient with an uncompensated course of type 2 diabetes with insufficient effectiveness of therapeuticGlibenclamide dosages.

The aim – to study the effects of quercetin on the functional status of platelets and blood viscosity in elderly patients with metabolic syndrome (MS). Materials and methods. Fifty patients with MS at the age of 60–75 years, who were equally distributed into the experimental and control groups, were examined. Patients of the experimental group received quercetin for 3 months («Quertin», PJSC SIC «Borshchahivskiy CPP», Ukraine) 80 mg 3 times a day. The control group received placebo for the same period of time. Before and after the treatment, MS criteria, platelet aggregation ability, blood viscosity and serum lipid levels were assessed. Results and discussion. After quercetin course, the rheological blood properties improved, that is its viscosity, spontaneous and induced platelet aggregation decreased. A statistically significant decrease in serum total cholesterol and LDL cholesterol levels was noted. Correlation analysis showed that an improvement in blood viscosity occurred due to favourable changes in the lipid spectrum and a decrease in the aggregation ability of blood cells. Conclusions. The obtained results indicate that in elderly patients with metabolic syndrome a course (within 3 months) use of quercetin reduces manifestations of dyslipidemia, increases spontaneous and induced platelet aggregation, contributes to an increase in the erythrocyte deformability index, which together lead to the decrease of blood viscosity, as one of the risk factors for the development of complications in metabolic syndrome.